AF and heart failure are emerging epidemics worldwide. Several recent trials have provided a growing evidence base for the benefits of catheter ablation in this patient group, which are yet to be universally adopted in clinical practice guidelines. This paper provides a summary of recent developments in this field and provides pragmatic advice to the treating physician regarding the appropriate role of catheter ablation in the overall management of patients with comorbid AF and heart failure.
Heart failure (HF) and AF are two conditions that are increasing in prevalence worldwide.
1,2 They frequently co-exist and in recent years, the clinical and physiological intersection between arrhythmia and HF has become an area of renewed interest, particularly as interventional treatments for rhythm disorders have advanced and moved into the mainstream of cardiac management. In particular, AF, the most frequently encountered cardiac arrhythmia, is now no longer considered as a passive bystander in the setting of HF, but rather an active determinant of clinical outcome,and in some circumstances, the critical driver of the HF itself. [3] [4] [5] In this modern context, it is important to re-evaluate the role of existing medical and interventional strategies in the management of patients with co-morbid AF and HF.
Older Studies and Their Limitations
The management of AF in HF has been coloured by two early large randomised trials which demonstrated no mortality benefit of pharmacological rhythm control over rate control. In what is still the largest randomised study ever conducted in AF, the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial evaluated overall mortality in 4,060 patients with varying AF burdens, 26% of whom had HF. 6 Patients were randomised to a strategy of pharmacological rhythm control (n=2,033) or rate control (n=2,027).
No difference was seen between the groups at 5 years, and there was a trend towards a worsened outcome in the rhythm control group (p=0.08).
Less well-known is a detailed sub-analysis of the data showing that the presence of sinus rhythm (SR) was associated with a significantly reduced mortality (HR 0.54; p<0.0001) that was largely offset by the increased mortality associated with anti-arrhythmic medical therapy to achieve SR, predominately (63%) amiodarone (HR 1.41; p=0.0005). 7 Additionally, HF symptoms were also significantly improved with rhythm control. and also showed no difference in mortality (p=0.59). 9 There are two crucial limitations of this study, which largely reflect the limitations of rhythm control management at the time. Firstly, amiodarone, known to be associated with increased mortality, was the rhythm control agent used in the majority (84%) of patients. Ablation was used in only 3.2% of patients. Secondly, it is important to note the study compared treatment strategies (rhythm control to rate control) and so was inherently limited by the poor efficacy of medical rhythm control strategies to maintain durable SR. At 5 years follow-up, only 42% of patients in the rhythm control arm were free from AF. This limited the study's ability to assess the effect of durable SR upon outcome.
Despite these limitations, these studies continue to influence the current clinical guidelines for management of AF, including in those with concurrent HF.
Catheter Ablation for AF in Heart Failure
The recent advent of catheter ablation as a mainstream treatment for AF has allowed the restoration of SR with improved efficacy and without the toxicities of long-term anti-arrhythmic therapy. Consequently, a The Interaction of AF and Heart Failure AF and HF share several pathophysiological mechanisms, each of which promote the progression of the other. AF drives HF by three primary mechanisms:
• tachycardia; 15 • ventricular irregularity; 16 and
• the loss of atrial contractile function. 17 Irrespective of its aetiology, HF creates a physiological environment which facilitates the development and progression of AF through adverse atrial remodelling. [18] [19] This occurs through:
• raised filling pressures; 20 • abnormal calcium handling; 21 and
• the activation of neural-hormonal pathways which promote atrial stretch and fibrosis. 22 For this reason, AF and HF frequently co-exist with reported rates as high as 35% in some studies. 23 Disentangling the "chicken and egg" relationship between the two can be challenging for the treating physician, particularly as the symptoms of both conditions are often non-specific (such as exertional dyspnoea and fatigue) with palpitations often absent. In patients with dilated cardiomyopathy, the presence of AF at the time of initial presentation with HF has been reported as high as 68%. 5 Nonetheless, attempting to ascertain the contributory significance of the AF to the HF is crucial as the elimination of AF in some patients, may have a dramatic impact upon cardiac function.
AF-mediated Heart Failure
The ability of AF to cause systolic dysfunction has been somewhat underappreciated,particularly where the cause of HF is uncertain (often classed as idiopathic). 24 The recently reported Catheter Ablation
Versus Medical Rate Control in AF and Systolic Dysfunction (CAMERA-MRI) study evaluated 66 patients with persistent AF and LVEF ≤45%, who were randomised to either catheter ablation or continuing ongoing medical rate control (MRC). 5 All patients were on established anti-failure medical therapy and had optimal MRC at baseline. Patients underwent cardiac MRI at baseline and 6 months post randomisation. 
Limitations of Medical Rate Control
Importantly, the benefits of restoring SR for improving ventricular function seen in the CAMERA-MRI study were demonstrated even in well-managed rate-controlled AF. Average ventricular rates were within guideline criteria before randomisation and further improved in the MRC arm during the study period. While the concept of tachycardiamediated cardiomyopathy has been well-described, the ability for SR is the only treatment strategy that completely treats all three drivers of HF, thus explaining its benefit over pacing and atrioventricular node (AVN) ablation which are still unable to restore atrial contractile function. 26 As demonstrated in the CAMERA-MRI study, even maximal MRC is unable to match the average ventricular rates achieved by the restoration of SR. As such, MRC effectively only partially treats the tachycardia component, with no impact on the other mechanisms.
At 6 months, mean heart rate was significantly lower in the catheter ablation group (all of whom were in SR, compared to the MRC group, all of whom were in AF (67 ± 9.1 versus 86 ± 14 BPM; p<0.0001).
Similar findings were seen for resting and post exercise heart rates. for 58 patients undergoing catheter ablation, compared to 58 patients without HF. They found no impact of underlying structural heart disease upon outcome. 25 Similarly, the CASTLE-AF study included 46%
of patients with ischaemic cardiomyopathy and found no difference in the primary outcome, even when stratified by HF type (p=0.56). 4 In the CAMERA-MRI study, those patients with non-ischaemic cardiomyopathy with evidence of scarring using late gadolinium enhancement on cardiac MRI, still had a significant improvement in LVEF following catheter ablation, although the magnitude of such improvement was proportional to the extent of scarring present at baseline. 5 In contrast, recent multicentre series and a meta-analyses of catheter ablation in HF, suggested that the presence of structural heart disease and fibrosis predicted a worse long-term outcome with respect to LVEF improvement, freedom from AF and mortality. 12, 28, 29 Until more prospective studies are completed, which specifically compare clinical outcomes of patients with known structural heart disease including extensive fibrosis, the extent to which this feature should influence treatment decisions is unclear. Nonetheless, given the results of the CAMERA-MRI study, the presence of minimal fibrosis should likely not deter from an ablation strategy.
What Constitutes Success in Catheter Ablation for HF?
The vast majority of AF encountered in the setting of HF is persistent, Importantly, recent trials of catheter ablation in HF have measured AF burden in addition to the conventional definition of recurrence.
4-5,11
A post hoc analysis of the CASTLE-AF study, in which all participants had a dual chamber ICD or cardiac resynchronisation therapy (CRT) device implanted, demonstrated that recurrence (determined by AF >30 seconds) had no statistical relationship with the primary endpoint. 34 In contrast, an AF burden of 6% or less, predicted a 2.5-3.3-fold freedom from the primary endpoint, compared to those with AF burden >6%. In that study, although the average AF burden in the catheter ablation arm at final follow-up was 27%, the median AF burden was 0%, suggesting the majority of patients in the catheter ablation arm had actually no clinically significant AF, and the reported average may have been driven by a smaller number of patients with very high AF burdens.
Thus, AF burden reduction, rather than freedom from recurrence, is probably a far more useful treatment aim, and reported high rates of recurrence should not deter from the use of catheter ablation as an anti-heart failure treatment in patients with persistent AF and HF.
However, the exact magnitude of burden reduction required to derive clinical benefit is likely yet to be fully elucidated.
Limitations of Clinical Trials
It showed poor success rates (50% restoration to SR) and did not show a significant improvement in LVEF on cardiac MRI (CMR). 35 Additionally, a secondary analysis of patients in the CASTLE-AF study highlighted that those with LVEF <25% had a significantly higher occurrence of the primary endpoint (mortality or unplanned HF-related admission) compared to those with LVEF ≥25%. 4 These findings suggest that patients with more severe HF may not benefit from catheter ablation. Finally, given the nature of the intervention, blinding of study participants to treatment allocation was not possible.
However, in many studies, the endpoint adjudicators were blinded to treatment allocation.
Ongoing Trials of Catheter Ablation in Heart Failure
There The publication of these studies in due course will greatly improve our understanding of the role of catheter ablation in HF.
Risks, Complications and Cost-effectiveness of Catheter Ablation
Despite the presence of systolic dysfunction, several prospective and retrospective analyses have shown generally low complication rates in patients with concurrent AF and HF, [4] [5] or at least rates comparable to patients without HF. 36 Although not overtly apparent in large published data sets, perceivably patients with more severe HF phenotypes may have higher rates of thrombo-embolic complications. 35, 37 Particular attention should be paid to pre-procedural, intraprocedural and post-procedural anti-coagulation with uninterrupted anti-coagulation strategies with either vitamin K antagonists or direct-acting oral anti-coagulants (DOACs) being the preferred option, to further minimise the risk of thrombo-embolism. [38] [39] [40] As with all AF ablation procedures, detailed discussion of the recognised risks of AF ablation (including stroke, cardiac tamponade, atrio-oesophogeal fistula, groin complications and adjacent nerve injury), should be central to informed consent.
Cost-effectiveness analyses of AF ablation are generally lacking.
However, the weight of data suggests that the cost:benefit ratio favours ablation in younger, highly symptomatic patients with poor response to anti-arrhythmic medications, and frequent hospitalisations. 40 This most ardently applies to patients with concurrent HF who frequently fail medical therapy and frequently require hospitalisation in the setting of AF-mediated acute on chronic exacerbations of HF. Nonetheless, a specific cost-effectiveness of analysis of ablation in AF and HF patients is yet to be formally undertaken.
Limitations of Current Clinical Guidelines
Current guidelines are yet to be updated to reflect the emerging role 
Clinical Perspective
• An increasing body of evidence suggests that catheter ablation for AF is effective, feasible and safe with improvements in symptoms, ventricular function, reduced heart failure-related hospitalisation and mortality.
• Although yet to be formally reflected in clinical guidelines, catheter ablation for AF in patients with AF should be strongly considered in patients with heart failure, particularly those unable or unwilling to take anti-arrhythmic drug therapy, such as amiodarone.
• In patients with AF and an otherwise unexplained cardiomyopathy, cardiac MRI can be a useful stratification tool. The absence of scarring is suggestive of an underlying AF-mediated cardiomyopathy, even in the setting of adequate rate control, and these patients will gain the most benefit from catheter ablation.
